US 12,492,230 B2
Antigenic peptides deriving from secretogranin V and uses thereof for the diagnosis and treatment of type 1 diabetes
Roberto Mallone, Paris (FR); Joëlle Vinh, Paris (FR); Yann Verdier, Paris (FR); Decio Laks Eizirik, Brussels (BE); Maikel Luis Colli, Brussels (BE); Georgia Afonso, Paris (FR); and Sergio Gonzalez-Duque, Paris (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); UNIVERSITE DE PARIS, Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris, Paris (FR); and Université Libre de Bruxelles, Brussels (BE)
Appl. No. 16/981,352
Filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); Universite de Paris, Paris (FR); Centre National de la Recherche Scientifique (CNRS), Paris (FR); Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris, Paris (FR); and Université Libre de Bruxelles, Brussels (BE)
PCT Filed Mar. 15, 2019, PCT No. PCT/EP2019/056539
§ 371(c)(1), (2) Date Sep. 16, 2020,
PCT Pub. No. WO2019/175380, PCT Pub. Date Sep. 19, 2019.
Claims priority of application No. 18305286 (EP), filed on Mar. 16, 2018.
Prior Publication US 2021/0070819 A1, Mar. 11, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 39/00 (2006.01); C07K 14/74 (2006.01); C07K 16/18 (2006.01)
CPC C07K 14/47 (2013.01) [A61K 39/0008 (2013.01); C07K 14/70539 (2013.01); C07K 16/18 (2013.01); A61K 2039/572 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01)] 18 Claims
 
1. A composition comprising
an isolated peptide derived from secretogranin V comprising:
at least 8 consecutive amino acids in the sequence ranging from the amino acid residue at
position 171 to the amino acid residue at position 215 in SEQ ID NO:2 (SCG5-009) and an adjuvant, wherein the length of the peptide consists of 8-21 amino acids.